Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
To systematically assess the effect of metformin on colorectal cancer (CRC) risk and mortality in type 2 diabetes mellitus (T2DM) patients. We conducted a systematic search of PubMed, Web of Science, and the Cochrane Library databases for relevant articles before August 2015. Two investigators identified and extracted data independently. We adopted adjusted estimates to calculate summary estimates with 95% confidence interval (CI) using either a fixed-effects or a random-effects model. Subgroup and sensitivity analyses were conducted to evaluate the robustness of the pooled results. The risk of publication bias was assessed by examining funnel plot asymmetry as well as Begg test and Egger test. Fifteen studies on CRC incidence and 6 studies on CRC survival were finally included in our meta-analysis. The pooled odds ratio (OR) of observational studies illustrated that a slight 10% reduction of CRC incidence was associated with metformin use (OR = 0.90, 95% CI: 0.85-0.96). Furthermore, the pooled hazard ratio (HR) revealed an improved survival outcome for metformin users in CRC patients compared to nonusers (HR = 0.68, 95% CI: 0.58-081). There was no publication bias across studies. Our meta-analysis demonstrated that metformin therapy could slightly reduce CRC incidence and moderately improve the survival outcomes in patients with T2DM. More prospective studies are warranted to certify this protective association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Sex differences also are reported with women at higher risk than men for oral, gastric, colorectal, and kidney cancers as well as leukemia, but with decreased risk for liver cancer.1772,1773”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1772]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“Because of the limited number of included studies, it was difficult to confirm whether the publication bias exists in our meta-analysis.(46)”
ResultRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Cancer treatment and survivorship statistics, 2014
DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21235 · Cited by 2,779
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · cited 1×
“Previous studies suggested that T2DM is closely related with the risk and prognosis of CRC, since they share several common risk factors, such as obesity, smoking, drinking, the western diet, and lack of exercise.(11) T2DM may contribute to the development of CRC through several mechanisms, including hyperglycemia, ox…”
BackgroundStewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134 · cited 1×
“METHODS This meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and MetaAnalysis (PRISMA) guidelines.(21) Search Strategy We (HXK and STT) independently searched Medline, Web of Science, and the Cochrane Library databases for all relevant studies before August 2015.”
MethodEdwards, B. K., Ward, E., Kohler, B. A., Eheman, C., Zauber, A. G., Anderson, R. N., Jemal, A., Schymura, M. J., Lansdorp‐Vogelaar, I., Seeff, L. C., et al. (2010) · Cancer · doi:10.1002/cncr.24760 · Cited by 2,002
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated
Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.309.6965.1351 · Cited by 1,017
Research works printed but not linked: 1
- Oliveria, 2008, Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome, Clinical Research & Reviews, 2, 47
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Repurposing metformin for the prevention of cancer and cancer recurrence
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 297
Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation
Limagne, E., Thibaudin, M., Euvrard, R., Berger, H., Chalons, P., Végan, F., Humblin, E., Boidot, R., Rébé, C., Derangère, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.004 · Cited by 138
“Notably, it has been shown that cancer rates in diabetics using metformin are lower than in patients using other insulin-sensitizing agents or insulin (Chlebowski et al., 2012; Gong et al., 2016; He et al., 2016).”
BackgroundThe Potential Effect of Metformin on Cancer: An Umbrella Review
Yu, H., Zhong, X., Gao, P., Shi, J., Wu, Z., Guo, Z., Wang, Z., & Song, Y. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00617 · Cited by 135
“(27) Colorectal cancer ++ + + + – – – –”
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
Meireles, C. G., Pereira, S. A., Valadares, L. P., Rêgo, D. F., Simeoni, L. A., Guerra, E. N. S., & Lofrano‐Porto, A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.120 · Cited by 122
Metadata
- Authors
- He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M.
- Affiliations
- Sir Run Run Shaw Hospital (CN)
- Corresponding author
- Sun, Lei-min
- ORCID
- Sun, Lei-min
- Venue
- Medicine
- Published
- 2016-02
- Volume
- 95
- Issue
- 7
- Pages
- e2749
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC4998616
- OpenAlex
- W2285738189
- Cited by
- 59
- References
- 55
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 9 · 2021: 6 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 15 · 2016: 5
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81302070, 81372623)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metformin, colorectal cancer, type 2 diabetes, colorectal cancer incidence, colorectal cancer survival, chemoprevention, drug repurposing
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Colorectal Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. https://app.cochat.ai/papers/10.1097/md.0000000000002749
- The paper
- He, X.-K., Su, T.-T., Si, J.-M., & Sun, L.-M. (2016). Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine. https://doi.org/10.1097/md.0000000000002749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.